NCT06126718View on ClinicalTrials.gov

Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions
Psoriasis
Interventions
DRUG

BR201

One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given

DRUG

Cosentyx（Secukinumab ）

One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given

Trial Locations (1)

266000

The Affiliated Hospital of Qingdao University, Qingdao

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY